BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 1,044 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 1,044 shares of the stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $323.69, for a total value of $337,932.36. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, July 8th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The shares were sold at an average price of $302.46, for a total transaction of $200,833.44.
• On Tuesday, June 16th, Chan Henry Lee sold 590 shares of BeOne Medicines stock. The shares were sold at an average price of $265.98, for a total transaction of $156,928.20.
• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The stock was sold at an average price of $257.63, for a total transaction of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The stock was sold at an average price of $270.42, for a total transaction of $235,535.82.
• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $310.72, for a total transaction of $103,159.04.

BeOne Medicines Price Performance

BeOne Medicines stock opened at $313.77 on Tuesday. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The firm has a 50 day moving average price of $293.57 and a 200 day moving average price of $308.92. The company has a market cap of $34.43 billion, a price-to-earnings ratio of 70.19 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The company had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. Sell-side analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ONC shares. Leerink Partners boosted their price target on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Guggenheim raised their price objective on BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Wells Fargo & Company began coverage on BeOne Medicines in a research note on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective on the stock. Zacks Research downgraded shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $394.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. EFG International AG acquired a new stake in BeOne Medicines during the 4th quarter valued at $25,000. Leonteq Securities AG acquired a new position in BeOne Medicines in the 4th quarter worth $35,000. Daiwa Securities Group Inc. acquired a new position in BeOne Medicines in the 2nd quarter worth $35,000. CWM LLC boosted its position in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after buying an additional 39 shares during the last quarter. Finally, Group One Trading LLC purchased a new position in BeOne Medicines in the 4th quarter valued at about $61,000. 48.55% of the stock is owned by institutional investors and hedge funds.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.